证券代码：600739 证券简称：辽宁成大 公告编号：2025-065 辽宁成大股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.02元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/29 | － | 2025/7/30 | 2025/7/30 | 差异化分红送转： 是 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 13 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比例） 由于公司本次进行差异化分红，上述公式中现金红利、流通股份变动比例 ...

Core Viewpoint - The Chinese innovative drug industry is experiencing significant growth in the first half of 2025, driven by policy benefits and international breakthroughs, with leading companies achieving explosive growth due to technological barriers and commercialization capabilities [1]. Company Performance Summaries - **Shuanglu Pharmaceutical**: Expected net profit for H1 2025 is between 100 million and 135 million RMB, a year-on-year increase of 237.95% to 356.24% from 29.59 million RMB in the same period last year, primarily benefiting from financial asset returns and breakthroughs in innovative drug pipelines [3][4]. - **Sino Biopharmaceutical**: Anticipated net profit ranges from 77.03 million to 94.14 million RMB, reflecting a year-on-year increase of 253.54% to 332.10%, driven by strong performance in peptide raw material exports [5][7]. - **Microchip Biotech**: Expected net profit of approximately 30.06 million RMB, representing a 173% increase, attributed to the inclusion of its core product (Sida Benamine) in medical insurance and optimized sales strategies [8][10]. - **Buchang Pharmaceutical**: Projected net profit between 488 million and 708 million RMB, a year-on-year increase of 110.88% to 205.94%, due to increased sales scale and reduced production costs [11][13]. - **Ganli Pharmaceutical**: Expected net profit of 600 million to 640 million RMB, a year-on-year increase of 100.73% to 114.12%, driven by significant revenue growth and refined expense management [15][16]. - **Shanghai Pharmaceuticals**: Anticipated net profit of 4.45 billion RMB, an increase of approximately 52% from the previous year, following the acquisition of a 10% stake in Shanghai Hengrui Medicine [17][18]. - **Liaoning Chengda**: Expected net profit between 689 million and 735 million RMB, a year-on-year increase of 50% to 60%, supported by a dual-driven strategy of healthcare and financial investment [19][21]. - **WuXi AppTec**: Projected net profit of approximately 6.3 billion RMB, a year-on-year increase of about 44.43%, driven by optimized CRDMO business models and significant non-operating gains from stock sales [23][25]. - **Notai Biopharmaceutical**: Expected net profit between 300 million and 330 million RMB, a year-on-year increase of 32.06% to 45.27%, attributed to sales growth in peptide raw materials [27][29]. - **I-Wu Biotech**: Anticipated net profit between 170 million and 180 million RMB, reflecting a year-on-year increase of 13.92% to 23.97%, focusing on allergy disease treatment products [30][31]. Industry Trends - The performance divergence in the innovative drug industry in 2025 indicates a shift from "scale competition" to "technological competition," with companies possessing genuine innovation capabilities and international layouts expected to lead, while those relying on capital operations or policy arbitrage face growth challenges [32].

[Core Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company forecasts a substantial increase exceeding 50% in both net profit attributable to shareholders and non-recurring net profit for H1 2025, indicating robust core business profitability 2025 Half-Year Performance Forecast | Metric | Estimated Amount (million CNY) | YoY Growth (%) | | :--- | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | 689.16 - 735.10 | 50.00 - 60.00 | | **Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items** | 684.13 - 735.07 | 50.30 - 61.50 | - This performance forecast represents the company's preliminary estimation based on operational conditions, unaudited by a certified public accountant[3](index=3&type=chunk) [Review of Prior Period Performance](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) The report provides 2024 prior period financial data as a comparative baseline, showing net profit attributable to shareholders at **CNY 459.44 million** and non-recurring net profit at **CNY 455.16 million** 2024 Half-Year (Prior Period) Performance | Metric | Amount (million CNY) | | :--- | :--- | | **Total Profit** | 492.72 | | **Net Profit Attributable to Parent Company Shareholders** | 459.44 | | **Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items** | 455.16 | | **Earnings Per Share (CNY)** | 0.3018 | [Performance Growth Drivers](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%A2%9E%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) Significant performance growth is primarily driven by increased investment income, attributed to the company's dual-driven strategy in healthcare and financial investments - The primary reason for the significant performance growth this period is the increase in the company's investment income[7](index=7&type=chunk) - The company diligently implements its dual-driven development strategy, focusing on 'pharmaceutical and healthcare industries alongside financial investments,' maintaining steady progress to enhance operational quality and efficiency[7](index=7&type=chunk) [Risk Warning and Other Notes](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) This performance forecast is based on unaudited preliminary calculations, with final data subject to the officially disclosed half-year report, cautioning investors on investment risks - The data in this performance forecast represents preliminary results based on the company's finance department's professional judgment, unaudited[8](index=8&type=chunk) - Final performance data will be subject to the company's officially disclosed 2025 half-year report, reminding investors to be aware of investment risks[9](index=9&type=chunk)

Summary of Key Points Core Viewpoint - Liaoning Chengda (600739) has successfully completed the repayment of its first phase of medium-term notes for 2022, amounting to 1 billion RMB, with a maturity of three years and a coupon rate of 5.5% [2][3]. Trading Information - As of July 11, 2025, Liaoning Chengda's stock closed at 11.66 RMB, up by 1.66%, with a turnover rate of 1.83%, a trading volume of 279,900 shares, and a total transaction value of 325 million RMB [1]. - On the same day, the capital flow for Liaoning Chengda showed a net outflow of 17.84 million RMB from institutional investors, accounting for 5.48% of the total transaction value [2][3]. - Retail investors contributed a net inflow of 16.01 million RMB, representing 4.92% of the total transaction value, while speculative funds saw a net inflow of 1.83 million RMB, making up 0.56% of the total transaction value [2]. Company Announcements - Liaoning Chengda announced the completion of the repayment of the principal and interest for the first phase of its medium-term notes issued in 2022, which had a total issuance amount of 1 billion RMB and a maturity of three years [2][3]. - The company had previously registered for a medium-term note issuance limit of up to 5 billion RMB, approved by the shareholders' meeting on August 3, 2020 [2].

Core Viewpoint - Liaoning Chengda's stock price increased by 5.9% this week, closing at 11.66 yuan, with a total market value of 17.836 billion yuan as of July 11, 2025 [1] Group 1: Stock Performance - As of July 11, 2025, Liaoning Chengda's stock closed at 11.66 yuan, up from 11.01 yuan the previous week, marking a 5.9% increase [1] - The stock reached a peak price of 11.75 yuan on July 11, 2025, and a low of 10.96 yuan on July 7, 2025 [1] - The company ranks 16th out of 50 in the bioproducts sector by market capitalization and 920th out of 5149 in the A-share market [1] Group 2: Company Announcements - Liaoning Chengda completed the repayment of its second short-term financing bond for 2024, which was due [2] - The company issued a short-term financing bond of 600 million yuan on July 4, 2024, with a one-year term and a coupon rate of 2.6%, which was fully repaid on July 5, 2025 [2] - On July 3, 2025, the company issued its first short-term financing bond for 2025, amounting to 800 million yuan with a coupon rate of 2.5%, primarily to repay existing debt [3] - The company also completed the repayment of its first medium-term note issued in 2022, which was 1 billion yuan with a three-year term and a coupon rate of 5.5%, due on July 11, 2025 [4]

2022 年度第一期中期票据已于 2025 年 7 月 11 日到期，公司已完成该期中 期票据本息的兑付。 特此公告。 辽宁成大股份有限公司董事会 辽宁成大股份有限公司 关于 2022 年度第一期中期票据到期兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2020 年 8 月 3 日，辽宁成大股份有限公司（以下简称"公司"）2020 年第 三次临时股东大会审议通过了《关于注册中期票据发行额度的议案》，公司向中 国银行间市场交易商协会申请注册金额不超过 50 亿元（含）人民币的中期票据 发行额度。公司于 2022 年 7 月 7 日完成了 2022 年度第一期中期票据的发行，金 额为人民币 10 亿元，期限为三年，票面利率为 5.5%，票面价格 100 元/百元面 值。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-063 2025 年 7 月 12 日 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025－062 辽宁成大股份有限公司 2025 年度第一期短期融资券发行结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 10 月 23 日，辽宁成大股份有限公司（以下简称"公司"）2024 年第二次 临时股东会审议通过了《关于注册短期融资券发行额度的议案》。中国银行间市场交 易商协会于 2025 年 6 月 27 日签发了《接受注册通知书》（中市协注【2025】CP68 号）， 接受公司短期融资券注册，注册金额为 30 亿元，注册额度自该通知书落款之日起 2 年内有效，由大连银行股份有限公司主承销。 公司于 2025 年 7 月 3 日在全国银行间市场发行规模为 8 亿元人民币的辽宁成大 股份有限公司 2025 年度第一期短期融资券，募集资金已于 2025 年 7 月 7 日全额到账， 募集资金主要用于偿还公司有息债务。现将发行结果公告如下： | | 基本信息 | | | | --- | --- | --- | --- | | 产品全称 | 辽宁成 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2022 年 5 月 31 日，辽宁成大股份有限公司（以下简称"公司"）2021 年年 度股东大会审议通过了《关于注册短期融资券发行额度的议案》，公司向中国银 行间市场交易商协会申请注册金额不超过 20 亿元（含）人民币的短期融资券发 行额度。公司于 2024 年 7 月 4 日完成了 2024 年度第二期短期融资券的发行，金 额为人民币 6 亿元，期限为一年，票面利率为 2.6%，票面价格 100 元/百元面值。 2024 年度第二期短期融资券已于 2025 年 7 月 5 日到期，公司已完成该期短 期融资券本息的兑付。 特此公告。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-061 辽宁成大股份有限公司 关于 2024 年度第二期短期融资券到期兑付公告 辽宁成大股份有限公司董事会 2025 年 7 月 8 日 ...

Group 1 - Company has received approval for the registration of short-term financing bonds amounting to RMB 3 billion, valid for 2 years from the date of the acceptance notice [1] - The main underwriter for the short-term financing bonds is Dalian Bank Co., Ltd., and the company can issue these bonds in tranches during the registration period [1] - The company will comply with relevant disclosure obligations as per the regulations governing non-financial corporate debt financing instruments [1] Group 2 - Company has provided a guarantee of RMB 10 million for its wholly-owned subsidiary, Chengda Hengrun (Dalian Free Trade Zone) Co., Ltd., to secure a comprehensive credit facility from China Everbright Bank [3][4] - The guarantee has been approved by the company's board and annual shareholders' meeting, ensuring compliance with internal decision-making procedures [4] - The total amount of external guarantees approved by the company and its subsidiaries is RMB 706.6 million, which represents 24.12% of the company's audited net assets for 2024 [5]

辽宁成大股份有限公司（以下简称"公司"）接到中国银行间市场交易商协 会的《接受注册通知书》（中市协注【2025】CP68 号），交易商协会决定接受公 司短期融资券注册。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-060 辽宁成大股份有限公司 关于公司短期融资券获准注册事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 7 月 1 日 根据《接受注册通知书》，公司本次短期融资券注册金额为人民币 30 亿元， 注册额度自《接受注册通知书》落款之日起 2 年内有效，由大连银行股份有限公 司主承销。公司在注册有效期内可分期发行短期融资券。 公司将按照《非金融企业债务融资工具注册发行规则》《非金融企业债务融 资工具注册工作规程》《非金融企业债务融资工具信息披露规则》及有关规则指 引规定，履行信息披露义务。 特此公告。 辽宁成大股份有限公司董事会 ...